CR20130156A - Proteínas de la unión a il-12/p40 (divisional 9599) - Google Patents
Proteínas de la unión a il-12/p40 (divisional 9599)Info
- Publication number
- CR20130156A CR20130156A CR20130156A CR20130156A CR20130156A CR 20130156 A CR20130156 A CR 20130156A CR 20130156 A CR20130156 A CR 20130156A CR 20130156 A CR20130156 A CR 20130156A CR 20130156 A CR20130156 A CR 20130156A
- Authority
- CR
- Costa Rica
- Prior art keywords
- hil
- antibodies
- proteins
- divisional
- union
- Prior art date
Links
- 102000013462 Interleukin-12 Human genes 0.000 title abstract 2
- 108010065805 Interleukin-12 Proteins 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 229940040731 human interleukin-12 Drugs 0.000 abstract 4
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 102000023732 binding proteins Human genes 0.000 abstract 1
- 108091008324 binding proteins Proteins 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
Abstract
Proteínas de unión a IL-12 p40, en particular anticuerpos que se unen a la interleuquina-12 humana (hIL-12) y/o IL-23 humana (hIL-23). Específicamente, la invención se relaciona con anticuerpos que son quiméricos, con injertos de CDR y anticuerpos humanizados. Los anticuerpos preferidos tienen gran afinidad por hIL-12 y/o hIL-23 y neutralizan la actividad de hIL-12 y/o hIL-23 in vitro y in vivo. Un anticuerpo de la invención puede ser un anticuerpo de longitud completa o una porción de unión al antígeno del mismo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US69567905P | 2005-06-30 | 2005-06-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20130156A true CR20130156A (es) | 2013-05-23 |
Family
ID=37605037
Family Applications (10)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR9599A CR9599A (es) | 2005-06-30 | 2007-12-18 | Proteinas de union a il-12/p40 |
CR20130154A CR20130154A (es) | 2005-06-30 | 2013-04-03 | Proteínas de la unión a il-12/p40 (divisional exp. 9599) |
CR20130149A CR20130149A (es) | 2005-06-30 | 2013-04-03 | Proteínas de la unión a il-12/p40 (divisional 9599) |
CR20130157A CR20130157A (es) | 2005-06-30 | 2013-04-03 | PROTEÍNAS DE LA UNIÓN A IL-12/P40 (Divisional 9599) |
CR20130153A CR20130153A (es) | 2005-06-30 | 2013-04-03 | PROTEÍNAS DE LA UNIÓN A IL-12/P40 (Divisional 9599) |
CR20130156A CR20130156A (es) | 2005-06-30 | 2013-04-03 | Proteínas de la unión a il-12/p40 (divisional 9599) |
CR20130151A CR20130151A (es) | 2005-06-30 | 2013-04-03 | PROTEÍNAS DE LA UNIÓN A IL-12/P40 (Divisional 9599) |
CR20130155A CR20130155A (es) | 2005-06-30 | 2013-04-03 | PROTEÍNAS DE LA UNIÓN A IL-12/P40 (Divisional 9599) |
CR20130150A CR20130150A (es) | 2005-06-30 | 2013-04-03 | Proteínas de la unión a il-12/p40 (divisional exp. 9599) |
CR20130152A CR20130152A (es) | 2005-06-30 | 2013-04-03 | Proteínas de la unión a il-12/p40 (divisional 9599) |
Family Applications Before (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR9599A CR9599A (es) | 2005-06-30 | 2007-12-18 | Proteinas de union a il-12/p40 |
CR20130154A CR20130154A (es) | 2005-06-30 | 2013-04-03 | Proteínas de la unión a il-12/p40 (divisional exp. 9599) |
CR20130149A CR20130149A (es) | 2005-06-30 | 2013-04-03 | Proteínas de la unión a il-12/p40 (divisional 9599) |
CR20130157A CR20130157A (es) | 2005-06-30 | 2013-04-03 | PROTEÍNAS DE LA UNIÓN A IL-12/P40 (Divisional 9599) |
CR20130153A CR20130153A (es) | 2005-06-30 | 2013-04-03 | PROTEÍNAS DE LA UNIÓN A IL-12/P40 (Divisional 9599) |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20130151A CR20130151A (es) | 2005-06-30 | 2013-04-03 | PROTEÍNAS DE LA UNIÓN A IL-12/P40 (Divisional 9599) |
CR20130155A CR20130155A (es) | 2005-06-30 | 2013-04-03 | PROTEÍNAS DE LA UNIÓN A IL-12/P40 (Divisional 9599) |
CR20130150A CR20130150A (es) | 2005-06-30 | 2013-04-03 | Proteínas de la unión a il-12/p40 (divisional exp. 9599) |
CR20130152A CR20130152A (es) | 2005-06-30 | 2013-04-03 | Proteínas de la unión a il-12/p40 (divisional 9599) |
Country Status (18)
Country | Link |
---|---|
US (3) | US7700739B2 (es) |
EP (1) | EP1907421A4 (es) |
JP (2) | JP5396080B2 (es) |
KR (2) | KR20080028895A (es) |
CN (11) | CN103145839A (es) |
AU (1) | AU2006265932B2 (es) |
BR (1) | BRPI0611714A2 (es) |
CA (2) | CA2848662A1 (es) |
CR (10) | CR9599A (es) |
IL (3) | IL187691A (es) |
MX (1) | MX2007016401A (es) |
NO (1) | NO20080557L (es) |
NZ (1) | NZ596992A (es) |
RU (1) | RU2461571C2 (es) |
TW (2) | TW200745160A (es) |
UA (1) | UA96922C2 (es) |
WO (1) | WO2007005608A2 (es) |
ZA (1) | ZA201201216B (es) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0611714A2 (pt) * | 2005-06-30 | 2009-01-13 | Abbott Lab | proteÍnas de ligaÇço a il-12/p40 |
BRPI0615297A2 (pt) | 2005-09-01 | 2011-05-17 | Schering Corp | antagonistas de il-23 e de il-17 para tratar doença inflamatória ocular auto-imune e seus usos |
KR20160033796A (ko) | 2006-03-28 | 2016-03-28 | 자블린 파머슈티칼스 인코포레이티드 | 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형 |
KR20100014674A (ko) | 2007-03-29 | 2010-02-10 | 아보트 러보러터리즈 | 결정성 항-사람 il-12 항체 |
US20090232801A1 (en) * | 2007-05-30 | 2009-09-17 | Abbot Laboratories | Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof |
AU2008328779B2 (en) | 2007-11-27 | 2014-06-05 | Ablynx N.V. | Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors |
CN104188911A (zh) | 2008-01-15 | 2014-12-10 | Abbvie德国有限责任两合公司 | 粉末状蛋白质组合物及其制备方法 |
KR101781965B1 (ko) * | 2008-08-14 | 2017-09-27 | 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 | 항-il-12/il-23 항체 |
US20110229471A1 (en) | 2008-11-26 | 2011-09-22 | Cedars-Sinai Medical Center | Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease |
US20110165063A1 (en) * | 2009-01-29 | 2011-07-07 | Abbott Laboratories | Il-1 binding proteins |
EP2772269A3 (en) * | 2009-03-05 | 2015-01-14 | Abbvie Inc. | IL-17 binding proteins |
CN101935687B (zh) * | 2009-06-29 | 2012-11-07 | 中国科学院上海生命科学研究院 | 用IL-12p40 siRNA促进肝再生 |
AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
RU2012131099A (ru) * | 2009-12-29 | 2014-02-10 | Ф. Хоффманн-Ля Рош Аг | Препарат антитела |
US8999340B2 (en) * | 2010-03-01 | 2015-04-07 | Alexion Pharmaceuticals, Inc. | Methods for treating multiorgan, systemic degos' disease with a complement inhibitor |
UA107490C2 (uk) * | 2010-04-07 | 2015-01-12 | Еббві Інк. | TNF-α-ЗВ'ЯЗУВАЛЬНИЙ БІЛОК |
AR081246A1 (es) | 2010-05-14 | 2012-07-18 | Abbott Lab | Proteinas de union a il-1 |
ES2395801B1 (es) * | 2011-06-23 | 2014-06-06 | María Carmen PARDINA PALLEJÀ | "pentoxifilina por vía transvaginal para el tratamiento de la infertilidad" |
SG10201604104PA (en) | 2011-10-25 | 2016-07-28 | Prothena Therapeutics Ltd | Antibody formulations and methods |
US20140010820A1 (en) * | 2012-05-21 | 2014-01-09 | Abbvie, Inc. | Novel purification of non-human antibodies using protein a affinity chromatography |
CN111329994A (zh) * | 2012-10-03 | 2020-06-26 | 菲罗根股份公司 | 与炎性肠病有关的抗原 |
HUE038959T2 (hu) * | 2013-02-14 | 2018-12-28 | Faron Pharmaceuticals Oy | Eljárás akut légúti distressz szindrómával (ARDS) összefüggõ biomarkerek kimutatására, illetve eljárás az ARDS betegben történõ kifejlõdésének és kezelésének monitorozására |
CN110845618A (zh) * | 2013-02-26 | 2020-02-28 | 罗切格利卡特公司 | 双特异性t细胞活化抗原结合分子 |
WO2014160883A1 (en) | 2013-03-27 | 2014-10-02 | Cedars-Sinai Medical Center | Treating fibrosis and inflammation by inhibiting tl1a |
WO2015010108A1 (en) | 2013-07-19 | 2015-01-22 | Cedars-Sinai Medical Center | Signature of tl1a (tnfsf15) signaling pathway |
US9393177B2 (en) | 2013-08-20 | 2016-07-19 | Anutra Medical, Inc. | Cassette assembly for syringe fill system |
AU2015210930B2 (en) * | 2014-01-30 | 2020-04-30 | Coherus Biosciences, Inc. | Perfusion media |
USD763433S1 (en) | 2014-06-06 | 2016-08-09 | Anutra Medical, Inc. | Delivery system cassette |
USD774182S1 (en) | 2014-06-06 | 2016-12-13 | Anutra Medical, Inc. | Anesthetic delivery device |
USD750768S1 (en) | 2014-06-06 | 2016-03-01 | Anutra Medical, Inc. | Fluid administration syringe |
US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
RS63210B1 (sr) | 2015-11-03 | 2022-06-30 | Janssen Biotech Inc | Potkožne formulacije anti-cd38 antitela i njihova upotreba |
CN105353135A (zh) * | 2015-11-23 | 2016-02-24 | 中国人民解放军第三军医大学第一附属医院 | 阿尔茨海默病标志物的用途 |
JP7082945B2 (ja) | 2016-03-17 | 2022-06-09 | シーダーズ―シナイ メディカル センター | Rnaset2により炎症性腸疾患を診断する方法 |
CA3027204A1 (en) * | 2016-06-29 | 2018-01-04 | Checkpoint Therapeutics, Inc. | Pd-l1-specific antibodies and methods of using the same |
CN110121509B (zh) | 2016-10-26 | 2024-05-07 | 西达-赛奈医疗中心 | 中和抗tl1a单克隆抗体 |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
US11166985B2 (en) | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
BR112019023608A2 (pt) | 2017-05-12 | 2020-05-26 | Crispr Therapeutics Ag | Materiais e métodos para células manipuladas e seus usos em imuno-oncologia |
EP4233989A3 (en) | 2017-06-07 | 2023-10-11 | Shifamed Holdings, LLC | Intravascular fluid movement devices, systems, and methods of use |
WO2019094963A1 (en) | 2017-11-13 | 2019-05-16 | Shifamed Holdings, Llc | Intravascular fluid movement devices, systems, and methods of use |
CN117959583A (zh) | 2018-02-01 | 2024-05-03 | 施菲姆德控股有限责任公司 | 血管内血泵以及使用和制造方法 |
JP7332627B2 (ja) | 2018-04-25 | 2023-08-23 | プロメテウス バイオサイエンシーズ,インク. | 最適化された抗tl1a抗体 |
CA3099364A1 (en) | 2018-05-11 | 2019-11-14 | Crispr Therapeutics Ag | Methods and compositions for treating cancer comprising engineered t cells comprising modified chimeric antigen receptors |
AU2019297451A1 (en) * | 2018-07-03 | 2021-01-28 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
FI3883606T3 (fi) | 2018-09-24 | 2023-09-07 | Janssen Biotech Inc | Turvallinen ja tehokas menetelmä haavaisen paksusuolitulehduksen hoitamiseksi anti-il12/il23-vasta-aineella |
CA3134079A1 (en) | 2019-03-18 | 2020-09-24 | Janssen Biotech, Inc. | Method of treating psoriasis in pediatric subjects with anti-il12/il23 antibody |
CA3138633A1 (en) | 2019-04-30 | 2020-11-05 | Crispr Therapeutics Ag | Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19 |
JP2022540616A (ja) | 2019-07-12 | 2022-09-16 | シファメド・ホールディングス・エルエルシー | 血管内血液ポンプならびに製造および使用の方法 |
WO2021016372A1 (en) | 2019-07-22 | 2021-01-28 | Shifamed Holdings, Llc | Intravascular blood pumps with struts and methods of use and manufacture |
US20220298235A1 (en) * | 2019-07-30 | 2022-09-22 | Akeso Biopharma, Inc | Anti-human p40 protein domain antibody and use thereof |
US11724089B2 (en) | 2019-09-25 | 2023-08-15 | Shifamed Holdings, Llc | Intravascular blood pump systems and methods of use and control thereof |
MX2022004942A (es) | 2019-10-24 | 2022-07-27 | Prometheus Biosciences Inc | Anticuerpos humanizados contra el ligando 1a de tipo tnf (tl1a) y usos de los mismos. |
CN111812014B (zh) * | 2020-08-05 | 2023-04-18 | 上海市血液中心 | 一种基于纳米材料的血小板抗体检测方法和血小板保存方法 |
US20220202862A1 (en) * | 2020-12-31 | 2022-06-30 | Immatics US, Inc. | Cd8 polypeptides, compositions, and methods of using thereof |
CN113092202A (zh) * | 2021-03-25 | 2021-07-09 | 上海福君基因生物科技有限公司 | 一种胃癌预后预测装置 |
AU2022371454A1 (en) * | 2021-10-20 | 2024-04-18 | Synthekine, Inc. | Human il-12p40 variants and uses thereof |
Family Cites Families (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0092918B1 (en) * | 1982-04-22 | 1988-10-19 | Imperial Chemical Industries Plc | Continuous release formulations |
GB8308235D0 (en) * | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5807715A (en) * | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US5128326A (en) * | 1984-12-06 | 1992-07-07 | Biomatrix, Inc. | Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same |
US6492107B1 (en) * | 1986-11-20 | 2002-12-10 | Stuart Kauffman | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
EP1186660A3 (fr) * | 1985-03-30 | 2002-03-20 | KAUFFMAN, Stuart A. | Procédé d'obtension d'ADN, ARN, peptides, polypeptides ou protéines, par une technique de recombination d'ADN |
US4980286A (en) * | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
US5618920A (en) * | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5225539A (en) * | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
DE3883899T3 (de) * | 1987-03-18 | 1999-04-22 | Sb2 Inc | Geänderte antikörper. |
US5258498A (en) * | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
US4880078A (en) * | 1987-06-29 | 1989-11-14 | Honda Giken Kogyo Kabushiki Kaisha | Exhaust muffler |
EP1997891A1 (en) | 1988-09-02 | 2008-12-03 | Dyax Corporation | Generation and selection of recombinant varied binding proteins |
US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5750373A (en) | 1990-12-03 | 1998-05-12 | Genentech, Inc. | Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants |
AU634186B2 (en) | 1988-11-11 | 1993-02-18 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
CA2016841C (en) | 1989-05-16 | 1999-09-21 | William D. Huse | A method for producing polymers having a preselected activity |
WO1990014443A1 (en) | 1989-05-16 | 1990-11-29 | Huse William D | Co-expression of heteromeric receptors |
CA2016842A1 (en) | 1989-05-16 | 1990-11-16 | Richard A. Lerner | Method for tapping the immunological repertoire |
AU6430190A (en) | 1989-10-10 | 1991-05-16 | Pitman-Moore, Inc. | Sustained release composition for macromolecular proteins |
EP0550436A1 (en) * | 1989-11-06 | 1993-07-14 | Alkermes Controlled Therapeutics, Inc. | Protein microspheres and methods of using them |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
AU7247191A (en) | 1990-01-11 | 1991-08-05 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
US5780225A (en) * | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
US6075181A (en) * | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5427908A (en) * | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
ATE185601T1 (de) | 1990-07-10 | 1999-10-15 | Cambridge Antibody Tech | Verfahren zur herstellung von spezifischen bindungspaargliedern |
GB9015198D0 (en) * | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
CA2090126C (en) * | 1990-08-02 | 2002-10-22 | John W. Schrader | Methods for the production of proteins with a desired function |
JP3306063B2 (ja) | 1990-08-24 | 2002-07-24 | イグジス, インコーポレイテッド | ランダムコドンを有するオリゴヌクレオチドを合成する方法 |
US5698426A (en) * | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
JP3298879B2 (ja) | 1990-12-20 | 2002-07-08 | イグジス,インコーポレイテッド | 結合タンパク質の最適化 |
DK1820858T3 (da) | 1991-03-01 | 2009-11-02 | Dyax Corp | Kimært protein omfatende mikroprotein med to eller flere disulfidbindinger og udförelsesformer deraf |
WO1992018619A1 (en) | 1991-04-10 | 1992-10-29 | The Scripps Research Institute | Heterodimeric receptor libraries using phagemids |
ES2181673T3 (es) * | 1991-05-01 | 2003-03-01 | Jackson H M Found Military Med | Procedimiento de tratamiento de las enfermedades respiratorias infecciosas. |
EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
JPH07503124A (ja) | 1991-06-14 | 1995-04-06 | ゾーマ・コーポレーション | 微生物によって生産される抗体断片とそれらの複合体 |
DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
DK0605522T3 (da) | 1991-09-23 | 2000-01-17 | Medical Res Council | Fremgangsmåde til fremstilling af humaniserede antistoffer |
ES2136092T3 (es) * | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
ATE463573T1 (de) | 1991-12-02 | 2010-04-15 | Medimmune Ltd | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
ATE249840T1 (de) * | 1991-12-13 | 2003-10-15 | Xoma Corp | Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung |
US5714350A (en) * | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
US5912015A (en) * | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
US5733743A (en) * | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
NZ255101A (en) | 1992-07-24 | 1997-08-22 | Cell Genesys Inc | A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
US5934272A (en) * | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
WO1994018219A1 (en) | 1993-02-02 | 1994-08-18 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
US5565352A (en) * | 1993-11-24 | 1996-10-15 | Arch Development Corporation | Deubiquitinating enzyme: compositions and methods |
JPH09506262A (ja) | 1993-12-08 | 1997-06-24 | ジェンザイム・コーポレイション | 特異的抗体の製造方法 |
US5516637A (en) * | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
US6091001A (en) * | 1995-03-29 | 2000-07-18 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
US6130364A (en) * | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
US6019968A (en) * | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
JPH11503914A (ja) * | 1995-04-21 | 1999-04-06 | セル ジェネシス,インコーポレイテッド | 大ゲノムdna欠失の生成 |
AU710347B2 (en) * | 1995-08-31 | 1999-09-16 | Alkermes Controlled Therapeutics, Inc. | Composition for sustained release of an agent |
JP2978435B2 (ja) * | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
WO1997032572A2 (en) * | 1996-03-04 | 1997-09-12 | The Penn State Research Foundation | Materials and methods for enhancing cellular internalization |
US5714352A (en) * | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
US5874064A (en) * | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
US5985309A (en) * | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
US5855913A (en) * | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
US6699658B1 (en) * | 1996-05-31 | 2004-03-02 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
US5916771A (en) * | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
US5989463A (en) * | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
ES2284242T3 (es) * | 1998-01-23 | 2007-11-01 | F. Hoffmann-La Roche Ag | Anticuerpos contra il-12 humana. |
US5989263A (en) * | 1998-03-11 | 1999-11-23 | Arteria Medical Science L.L.C. | Hydraulically actuated dilatation mechanism for vessel dilatation and vascular prosthesis delivery and methods of use |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
EP2168984B1 (en) * | 1999-03-25 | 2012-08-29 | Abbott GmbH & Co. KG | Human antibodies that bind human IL-12 and methods for producing |
US6914128B1 (en) * | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
DK2270149T3 (en) | 1999-04-09 | 2016-05-09 | Kyowa Hakko Kirin Co Ltd | PROCEDURE TO CONTROL THE ACTIVITY OF IMMUNOLOGICAL FUNCTIONAL MOLECULE. |
WO2001098361A2 (en) * | 2000-06-22 | 2001-12-27 | Genentech, Inc. | Agonist anti-trk-c monoclonal antibodies |
US7449308B2 (en) * | 2000-06-28 | 2008-11-11 | Glycofi, Inc. | Combinatorial DNA library for producing modified N-glycans in lower eukaryotes |
DK1522590T3 (da) * | 2000-06-28 | 2009-12-21 | Glycofi Inc | Fremgangsmåde til fremstilling af modificerede glykoproteiner |
US6902734B2 (en) * | 2000-08-07 | 2005-06-07 | Centocor, Inc. | Anti-IL-12 antibodies and compositions thereof |
US8080247B2 (en) * | 2000-08-07 | 2011-12-20 | Janssen Biotech, Inc. | Anti-IL-12 antibodies |
CA2433353C (en) | 2000-12-28 | 2017-03-21 | Altus Biologics, Inc. | Crystals of whole antibodies and fragments thereof and methods for making and using them |
US7667004B2 (en) | 2001-04-17 | 2010-02-23 | Abmaxis, Inc. | Humanized antibodies against vascular endothelial growth factor |
EP1385544B1 (en) | 2001-04-30 | 2008-09-24 | Eli Lilly And Company | Humanized antibodies |
WO2002097048A2 (en) * | 2001-05-30 | 2002-12-05 | Centocor, Inc. | ANTI-p40 IMMUNOGLOBULIN DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES |
CA2451998A1 (en) | 2001-08-17 | 2003-02-27 | Eli Lilly And Company | Anti-a.beta. antibodies |
ATE346866T1 (de) | 2001-09-14 | 2006-12-15 | Affimed Therapeutics Ag | Multimerische, einzelkettige, tandem-fv- antikörper |
CA2462113C (en) * | 2001-10-01 | 2013-01-29 | Dyax Corp. | Multi-chain eukaryotic display vectors and uses thereof |
AU2002360278A1 (en) * | 2001-10-12 | 2003-11-11 | Coley Pharmaceutical Gmbh | Methods and products for enhancing immune responses using imidazoquinoline compounds |
US20030157108A1 (en) | 2001-10-25 | 2003-08-21 | Genentech, Inc. | Glycoprotein compositions |
US7510709B2 (en) * | 2002-10-30 | 2009-03-31 | Genentech, Inc. | Method of treating inflammatory disease by inhibition of IL-17 production |
US20060104968A1 (en) * | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
PT1603541E (pt) | 2003-03-05 | 2010-02-19 | Halozyme Inc | Glicoproteína hialuronidase solúvel (shasegp), processo para preparação da mesma, suas utilizações e composições farmacêuticas que a compreendem. |
WO2004101511A2 (en) | 2003-05-09 | 2004-11-25 | Protein Design Labs, Inc | Anti-ip-10 antibodies and methods of using thereof for the treatment of inflamatory bowel diseases |
CA2525184C (en) * | 2003-05-09 | 2012-10-30 | Centocor, Inc. | Il-23p40 specific immunoglobulin derived proteins, compositions, methods and uses |
EP1629012B1 (en) | 2003-05-31 | 2018-11-28 | Amgen Research (Munich) GmbH | Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders |
US20050042664A1 (en) * | 2003-08-22 | 2005-02-24 | Medimmune, Inc. | Humanization of antibodies |
CN1950496B (zh) | 2004-04-15 | 2015-02-04 | 格利科菲公司 | 在低等真核生物中产生半乳糖基化糖蛋白 |
BRPI0611714A2 (pt) * | 2005-06-30 | 2009-01-13 | Abbott Lab | proteÍnas de ligaÇço a il-12/p40 |
-
2006
- 2006-06-29 BR BRPI0611714-7A patent/BRPI0611714A2/pt not_active IP Right Cessation
- 2006-06-29 KR KR1020077030917A patent/KR20080028895A/ko not_active IP Right Cessation
- 2006-06-29 CN CN2013100523457A patent/CN103145839A/zh active Pending
- 2006-06-29 RU RU2008103312/10A patent/RU2461571C2/ru not_active IP Right Cessation
- 2006-06-29 WO PCT/US2006/025584 patent/WO2007005608A2/en active Application Filing
- 2006-06-29 UA UAA200801144A patent/UA96922C2/ru unknown
- 2006-06-29 AU AU2006265932A patent/AU2006265932B2/en not_active Ceased
- 2006-06-29 CN CN2013100523902A patent/CN103172738A/zh active Pending
- 2006-06-29 CN CN2013100523442A patent/CN103145838A/zh active Pending
- 2006-06-29 CA CA2848662A patent/CA2848662A1/en not_active Abandoned
- 2006-06-29 CN CN2013100525804A patent/CN103145841A/zh active Pending
- 2006-06-29 JP JP2008519612A patent/JP5396080B2/ja not_active Expired - Fee Related
- 2006-06-29 CN CN2013100523423A patent/CN103145837A/zh active Pending
- 2006-06-29 CN CN2013100523601A patent/CN103172737A/zh active Pending
- 2006-06-29 CN CN2006800240973A patent/CN101379085B/zh not_active Expired - Fee Related
- 2006-06-29 CN CN2013100525787A patent/CN103145840A/zh active Pending
- 2006-06-29 KR KR1020137014441A patent/KR20130080058A/ko not_active Application Discontinuation
- 2006-06-29 US US11/478,096 patent/US7700739B2/en active Active
- 2006-06-29 CN CN2013100523565A patent/CN103146708A/zh active Pending
- 2006-06-29 MX MX2007016401A patent/MX2007016401A/es active IP Right Grant
- 2006-06-29 EP EP20060785967 patent/EP1907421A4/en not_active Ceased
- 2006-06-29 TW TW095123725A patent/TW200745160A/zh unknown
- 2006-06-29 NZ NZ596992A patent/NZ596992A/xx not_active IP Right Cessation
- 2006-06-29 TW TW103113940A patent/TW201444869A/zh unknown
- 2006-06-29 CN CN2013100527956A patent/CN103172739A/zh active Pending
- 2006-06-29 CN CN2013100531542A patent/CN103145842A/zh active Pending
- 2006-06-29 CA CA002612239A patent/CA2612239A1/en not_active Abandoned
-
2007
- 2007-11-27 IL IL187691A patent/IL187691A/en not_active IP Right Cessation
- 2007-12-18 CR CR9599A patent/CR9599A/es unknown
-
2008
- 2008-01-30 NO NO20080557A patent/NO20080557L/no not_active Application Discontinuation
-
2010
- 2010-04-19 US US12/763,048 patent/US8629257B2/en not_active Expired - Fee Related
-
2011
- 2011-12-06 IL IL216803A patent/IL216803A0/en unknown
-
2012
- 2012-02-17 ZA ZA2012/01216A patent/ZA201201216B/en unknown
-
2013
- 2013-04-03 CR CR20130154A patent/CR20130154A/es unknown
- 2013-04-03 CR CR20130149A patent/CR20130149A/es unknown
- 2013-04-03 CR CR20130157A patent/CR20130157A/es unknown
- 2013-04-03 CR CR20130153A patent/CR20130153A/es unknown
- 2013-04-03 CR CR20130156A patent/CR20130156A/es unknown
- 2013-04-03 CR CR20130151A patent/CR20130151A/es unknown
- 2013-04-03 CR CR20130155A patent/CR20130155A/es unknown
- 2013-04-03 CR CR20130150A patent/CR20130150A/es unknown
- 2013-04-03 CR CR20130152A patent/CR20130152A/es unknown
- 2013-04-24 JP JP2013091454A patent/JP2013177405A/ja active Pending
- 2013-10-08 IL IL228793A patent/IL228793A0/en unknown
-
2014
- 2014-01-13 US US14/154,076 patent/US20140178332A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20130152A (es) | Proteínas de la unión a il-12/p40 (divisional 9599) | |
CR10656A (es) | Proteinas de union a interleuquina-13 | |
NO20071436L (no) | Humaniserte Anti-5T4 antistoffer og Anti-5T4 antistoff/calicheamicin konjugater | |
UA92504C2 (en) | Anti-myostatin monoclonal antibody | |
UY32949A (es) | Proteínas de unión a il-1 | |
DK1827492T3 (da) | Antistoffer rettet mod GPNMB og anvendelser deraf | |
GEP20094829B (en) | Fully human antibodies against human 4-1bb (cd137) | |
DE602006013029D1 (de) | Anti-egfr-antikörper | |
EA200870050A1 (ru) | Анти-il-17-антитела | |
HUP0300423A2 (hu) | Emberi interleukin-18-at megkötni képes antitestek és ezek előállítására és alkalmazására szolgáló eljárások | |
DK1685152T3 (da) | IL-18-bindingsproteiner | |
NZ594466A (en) | Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies | |
CO6400231A2 (es) | Proteínas de unión a il-1 | |
DK2135881T3 (da) | Antistoffer, som binder til det tumor-associerede antigen TAT10772, til diagnose og behandling af tumor | |
DK1716181T3 (da) | CDR-reparerede antistoffer | |
ATE520716T1 (de) | Humanisierter anti-cd4-antikörper mit immunsuppressiven eigenschaften | |
NO20054351D0 (no) | Monoklonalt antistoff og hybridom som produserer dette | |
TW200714290A (en) | Anti-M-CSF antibody compositions having reduced levels of endotoxin | |
UA94211C2 (ru) | Выделенное полностью человеческое моноклональное cd3 антитело | |
DE60238987D1 (de) | Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper | |
DK1730196T3 (da) | EphB4-bindende antistoffer til inhibering af antiogenese og tumorvækst | |
UA98100C2 (ru) | Гуманизированное моноклональное антитело, которое связывается с человеческим nogo и нейтрализует его | |
SG163559A1 (en) | Il-12/p40 binding proteins | |
MY150711A (en) | Il-12/p40 binding proteins | |
DOP2009000033A (es) | Proteinas de union a interleuquina-13 |